The Role of Pharmacogenomics in Postoperative Pain Management.
Acute pain
Chronic pain
Pain management
Pharmacogenetics
Pharmacogenomics
Postoperative pain
Precision medicine
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
9
9
2022
Statut:
ppublish
Résumé
Pharmacogenomics can improve pain management by considering individual variations in pain perception and susceptibility and sensitivity to medicines related to genetic diversity. Due to the subjective nature of pain and the fact that people respond differently to medicines, it can be challenging to develop a consistent and successful regimen for pain disorders. Numerous factors influence the outcome of pain treatment programs, but two stand out: altered perception of pain and varying responsiveness to analgesic medicines. Numerous polymorphisms in genes such as CYP2D6, OPRM1, and ABCB1 have been identified, culminating in a heterogeneous response to pain medication in people who have these genetic polymorphisms. Improved treatment regimens that factor in pharmacogenetic differences in patients would help reduce the risk of opioid dependency and help effectively treat postoperative pain.
Identifiants
pubmed: 36068475
doi: 10.1007/978-1-0716-2573-6_18
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-526Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Cornett EM, Carroll Turpin MA, Pinner A et al (2020) Pharmacogenomics of pain management: the impact of specific biological polymorphisms on drugs and metabolism. Curr Oncol Rep 22:18
pubmed: 32030524
Kaye AD, Garcia AJ, Hall OM et al (2019) Update on the pharmacogenomics of pain management. PGPM 12:125–143
pubmed: 31308726
pmcid: 6613192
Chaturvedi R, Alexander B, A’Court AM et al (2020) Genomics testing and personalized medicine in the preoperative setting: can it change outcomes in postoperative pain management? Best Pract Res Clin Anaesthesiol 34:283–295
pubmed: 32711834
Aroke EN, Kittelsrud JM (2020) Pharmacogenetics of postoperative pain management: a review. AANA J 88:229–236
pubmed: 32442101
Nurse Anesthesiology (2020) A primer to pharmacogenetics of postoperative pain management. Available from: https://nurseanesthesiology.aana.com/a-primer-to-pharmacogenetics-of-postoperative-pain-management
Nahin RL (2015) Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 16:769–780
pubmed: 26028573
pmcid: 4562413
Brekke M, Hjortdahl P, Kvien TK (2002) Severity of musculoskeletal pain: relations to socioeconomic inequality. Soc Sci Med 54:221–228
pubmed: 11824927
Fischer S, Doerr JM, Strahler J et al (2016) Stress exacerbates pain in the everyday lives of women with fibromyalgia syndrome – the role of cortisol and alpha-amylase. Psychoneuroendocrinology 63:68–77
pubmed: 26431802
Coulbault L, Beaussier M, Verstuyft C et al (2006) Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 79:316–324
pubmed: 16580900
Østerås B, Sigmundsson H, Haga M (2015) Perceived stress and musculoskeletal pain are prevalent and significantly associated in adolescents: an epidemiological cross-sectional study. BMC Public Health 15:1081
pubmed: 26498498
pmcid: 4619092
Periasamy S, Poovathai R, Pondiyadanar S (2014) Influences of gender on postoperative morphine consumption. J Clin Diagn Res 8:GC04–GC07
pubmed: 25653963
pmcid: 4316269
Si H, Yang T, Zeng Y et al (2017) Correlations between inflammatory cytokines, muscle damage markers and acute postoperative pain following primary total knee arthroplasty. BMC Musculoskelet Disord 18:265
pubmed: 28623906
pmcid: 5473999
Zhang J-M, An J (2007) Cytokines, inflammation, and pain. Int Anesthesiol Clin 45:27–37
pubmed: 17426506
pmcid: 2785020
Bair MJ, Robinson RL, Katon W et al (2003) Depression and pain comorbidity: a literature review. Arch Intern Med 163:2433–2445
pubmed: 14609780
Song T-J, Cho S-J, Kim W-J et al (2016) Anxiety and depression in tension-type headache: a population-based study. PLoS One 11:e0165316
pubmed: 27783660
pmcid: 5082613
Davies KA, Silman AJ, Macfarlane GJ et al (2009) The association between neighbourhood socio-economic status and the onset of chronic widespread pain: results from the EPIFUND study. Eur J Pain 13:635–640
pubmed: 18782674
pmcid: 2701988
Nielsen CS, Stubhaug A, Price DD et al (2008) Individual differences in pain sensitivity: genetic and environmental contributions. Pain 136:21–29
pubmed: 17692462
Mossey JM (2011) Defining racial and ethnic disparities in pain management. Clin Orthop Relat Res 469:1859–1870
pubmed: 21249483
pmcid: 3111792
Green CR, Anderson KO, Baker TA et al (2003) The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med 4:277–294
pubmed: 12974827
Reyes-Gibby CC, Aday LA, Todd KH et al (2007) Pain in aging community-dwelling adults in the United States: non-hispanic whites, non-hispanic blacks, and hispanics. J Pain 8:75–84
pubmed: 16949874
Agúndez JAG, Blanca M, Cornejo-García JA et al (2015) Pharmacogenomics of cyclooxygenases. Pharmacogenomics 16:501–522
pubmed: 25916522
Kaye AD, Garcia AJ, Hall OM et al (2019) Update on the pharmacogenomics of pain management. Pharmgenomics Pers Med 12:125–143
pubmed: 31308726
pmcid: 6613192
Theken KN, Lee CR, Gong L et al (2020) Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 108:191–200
pubmed: 32189324
Ramachandran A, Jaeschke H (2018) Acetaminophen toxicity: novel insights into mechanisms and future perspectives. Gene Expr 18:19–30
pubmed: 29054140
pmcid: 5885144
James LP, McGill MR, Roberts DW et al (2020) Advances in biomarker development in acetaminophen toxicity. Adv Clin Chem 98:35–50
pubmed: 32564787
Mazaleuskaya LL, Sangkuhl K, Thorn CF et al (2015) PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics 25:416–426
pubmed: 26049587
pmcid: 4498995
Hermanns H, Hollmann MW, Stevens MF et al (2019) Molecular mechanisms of action of systemic lidocaine in acute and chronic pain: a narrative review. Br J Anaesth 123:335–349
pubmed: 31303268
Wang JS, Backman JT, Taavitsainen P et al (2000) Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 28:959–965
pubmed: 10901707
Fang P, Tang P-F, Xu R-A et al (2017) Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. Drug Des Devel Ther 11:3503–3510
pubmed: 29263648
pmcid: 5724423
Zarei S, Costas Y, Orozco G et al (2020) A web-based pharmacogenomics search tool for precision medicine in perioperative care. J Pers Med 10:E65
Crews KR, Monte AA, Huddart R et al (2021) Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther 110(4):888–896
pubmed: 33387367
Awad ME, Padela MT, Sayeed Z et al (2019) Pharmacogenomic testing for postoperative pain optimization before total joint arthroplasty: a focus on drug-drug-gene interaction with commonly prescribed drugs and prior opioid use. JBJS Rev 7:e2
pubmed: 31094889
Lötsch J, von Hentig N, Freynhagen R et al (2009) Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 19:429–436
pubmed: 19514130
Sistonen J, Madadi P, Ross CJ et al (2012) Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther 91:692–699
pubmed: 22398969
Yang Z-Z, Li L, Wang L et al (2017) The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants. Acta Pharmacol Sin 38:1184–1194
pubmed: 28552915
pmcid: 5547550
Nielsen LM, Sverrisdóttir E, Stage TB et al (2017) Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics. Eur J Pharm Sci 99:337–342
pubmed: 28063968
Bastami S, Gupta A, Zackrisson A-L et al (2014) Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption. Basic Clin Pharmacol Toxicol 115:423–431
pubmed: 24703092
Ning M, Tao Y, Hu X et al (2019) Roles of UGT2B7 C802T gene polymorphism on the efficacy of morphine treatment on cancer pain among the Chinese han population. Niger J Clin Pract 22:1319–1323
pubmed: 31607718
Haage P, Kronstrand R, Josefsson M et al (2018) Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype. Pharmacol Res Perspect 6:e00419
pubmed: 29992026
pmcid: 6034060
Rollason V, Lloret-Linares C, Lorenzini KI et al (2020) Evaluation of phenotypic and genotypic variations of drug metabolising enzymes and transporters in chronic pain patients facing adverse drug reactions or non-response to analgesics: a retrospective study. J Pers Med 10:198
pubmed: 33121061
pmcid: 7711785
Lee J, Yoo H-D, Bae J-W et al (2019) Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6. Drug Des Devel Ther 13:1751–1761
pubmed: 31213765
pmcid: 6537040
Wendt FR, Novroski NMM, Rahikainen A-L et al (2019) A pathway-driven predictive model of tramadol pharmacogenetics. Eur J Hum Genet 27:1143–1156
pubmed: 30824817
pmcid: 6777452
Saiz-Rodríguez M, Ochoa D, Román M et al (2020) Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics. Pharmacogenomics 21:663–675
pubmed: 32538291
Tanaka H, Naito T, Sato H et al (2018) Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients. Eur J Clin Pharmacol 74:1461–1469
pubmed: 30051214
Stamer UM, Musshoff F, Stüber F et al (2016) Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Pain 157:2467–2475
pubmed: 27541716
Wang L, Wei C, Xiao F et al (2019) Influences of COMT rs4680 and OPRM1 rs1799971 polymorphisms on chronic postsurgical pain, acute pain, and analgesic consumption after elective cesarean delivery. Clin J Pain 35:31–36
pubmed: 30234521
Hosseinnejad K, Yin T, Gaskins JT et al (2019) Lack of influence by CYP3A4 and CYP3A5 genotypes on pain relief by hydrocodone in postoperative cesarean section pain management. J Appl Lab Med 3:954–964
pubmed: 31639687
Smith DM, Weitzel KW, Cavallari LH et al (2018) Clinical application of pharmacogenetics in pain management. Per Med 15:117–126
pubmed: 29714124
pmcid: 6460918
Stauble ME, Moore AW, Langman LJ et al (2014) Hydrocodone in postoperative personalized pain management: pro-drug or drug? Clin Chim Acta 429:26–29
pubmed: 24269714
Boswell MV, Stauble ME, Loyd GE et al (2013) The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone. Pain Physician 16:E227–E235
pubmed: 23703421
Umukoro NN, Aruldhas BW, Rossos R et al (2021) Pharmacogenomics of oxycodone: a narrative literature review. Pharmacogenomics 22:275–290
pubmed: 33728947
pmcid: 8050982
Huddart R, Clarke M, Altman RB et al (2018) PharmGKB summary. Pharmacogenet Genomics 28:230–237
Klepstad P, Fladvad T, Skorpen F et al (2011) Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 152:1139–1145
pubmed: 21398039
Zwisler ST, Enggaard TP, Mikkelsen S et al (2012) Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol 52:234–242
pubmed: 21383334
Qian Y, Gilliland TK, Markowitz JS (2020) The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin. Chem Biol Interact 316:108914
pubmed: 31837295
Lawford BR, Young RM, Noble EP et al (2000) The D2 dopamine receptor A1 allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 96:592–598
pubmed: 11054765
Takashina Y, Naito T, Mino Y et al (2012) Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet 27:414–421
pubmed: 22277678
Barratt DT, Bandak B, Klepstad P et al (2014) Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenet Genomics 24:185–194
pubmed: 24469018
Crist RC, Clarke T-K, Ang A et al (2013) An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology 38:2003–2010
pubmed: 23612435
pmcid: 3746708
Culp C, Kim HK, Abdi S (2021) Ketamine use for cancer and chronic pain management. Front Pharmacol 11:599721
pubmed: 33708116
pmcid: 7941211
Zheng X, Fang P, Bao S et al (2017) Function of 38 variants CYP2C9 polymorphism on ketamine metabolism in vitro. J Pharmacol Sci 135:8–13
pubmed: 28927781
Li Y, Jackson KA, Slon B et al (2015) CYP2B6 * 6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. Br J Clin Pharmacol 80:276–284
pubmed: 25702819
pmcid: 4541975
Stoker AD, Rosenfeld DM, Buras MR et al (2019) Evaluation of clinical factors associated with adverse drug events in patients receiving sub-anesthetic ketamine infusions. J Pain Res 12:3413–3421
pubmed: 31920366
pmcid: 6934144
Birgenheier NM, Stuart AR, Egan TD (2020) Soft drugs in anesthesia: remifentanil as prototype to modern anesthetic drug development. Curr Opin Anaesthesiol 33:499–505
pubmed: 32530892
Landau R (2012) Pharmacogenomic considerations in opioid analgesia. Pharmgenomics Pers Med 5:73–87
pubmed: 23226064
pmcid: 3513230
Brasch-Andersen C, Møller MU, Christiansen L et al (2011) A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). Eur J Clin Pharmacol 67:1131–1137
pubmed: 21614492
Trescot AM, Faynboym S (2014) A review of the role of genetic testing in pain medicine. Pain Physician 17:425–445
pubmed: 25247900
Rudd RA, Aleshire N, Zibbell JE et al (2016) Increases in drug and opioid overdose deaths – United States, 2000-2014. MMWR Morb Mortal Wkly Rep 64:1378–1382
pubmed: 26720857
Florence C, Luo F, Xu L et al (2016) The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. Med Care 54:901–906
pubmed: 27623005
pmcid: 5975355
Faucett J, Gordon N, Levine J (1994) Differences in postoperative pain severity among four ethnic groups. J Pain Symptom Manag 9:383–389
Fillingim RB (2000) Sex, gender, and pain: women and men really are different. Curr Rev Pain 4:24–30
pubmed: 10998712
Hah JM, Bateman BT, Ratliff J et al (2017) Chronic opioid use after surgery: implications for perioperative management in the face of the opioid epidemic. Anesth Analg 125:1733–1740
pubmed: 29049117
pmcid: 6119469
Neskovic N, Mandic D, Marczi S et al (2021) Different pharmacokinetics of tramadol, O-demethyltramadol and N-demethyltramadol in postoperative surgical patients from those observed in medical patients. Front Pharmacol 12:656748
pubmed: 33935773
pmcid: 8082457
Smith DM, Weitzel KW, Elsey AR et al (2019) CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med 21:1842–1850
pubmed: 30670877
pmcid: 6650382